Cardinal Health, University of Washington align for molecular imaging trials

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Cardinal Health and the University of Washington (UW) have collaborated for the use molecular imaging in clinical investigations and trials.

Through this collaboration, the UW’s department of radiology will relocate a portion of its on-campus molecular tracer laboratories into Cardinal’s PET manufacturing facility in Seattle.

The UW laboratories that are part of the move will include one operated by John Grierson, PhD, who developed the PET agent F-18 fluorothymidine (FLT), which is now distributed in the U.S. through Cardinal, and is being used in clinical trials.

UW’s department of radiology will have access to Cardinal’s cyclotron, radiopharmaceutical products and research support services, added Cardinal, headquartered in Dublin, Ohio.